Hisun Pharmaceutical released its 2026 interim report. Total operating revenue was 4.475 billion yuan, and net profit attributable to the parent company was 636 million yuan, an increase of 337 million yuan compared with the same period last year, up 112.82% year on year. Net cash inflow from operating activities was 832 million yuan. The asset-liability ratio was 31.84%, gross margin was 55.58%, ROE was 7.08%, and diluted earnings per share was 0.55 yuan. The company had 48,800 shareholders, and the top ten shareholders held 45.81% of the total share capital.
Zhejiang Hisun Pharmaceutical Co LtdNet profit up 112.82% YoY in interim report
